The Dermatology Unit of Bayer HealthCare
cordially requests your presence
at an educational program

Treatment of Common Skin Disorders: FINACEA® (azelaic acid) Gel, 15% for Mild to Moderate Papulopustular Rosacea, Desonate® (desonide) Gel 0.05% Gel for Mild to Moderate Atopic Dermatitis

Speaker: **Helen Bonnae T Nawara, MSN,RN,CPNP**
Children's Doctors of Texas

Date: **Wednesday, June 20, 2012**

Time: **6:00 PM**

Location: **Perry's Grille and Steakhouse**

Address: **487 Bay Area Boulevard**
Houston, TX 77058

If you'd like to attend, please RSVP: **https://www.BHC-RSVP.com**

Please RSVP at your earliest convenience as space is limited.

Program Code: **PRF601**

This presentation has been designed to communicate valuable information to Healthcare Professionals; therefore, the attendance of spouses and guests is not appropriate.

Bayer HealthCare

FINACEA® (azelaic acid) Gel, 15%

INDICATION AND USAGE

FINACEA (azelaic acid) Gel, 15% is indicated for topical treatment of inflammatory papules and pustules of mild to moderate rosacea.

Although some reduction of erythema which was present in patients with papules and pustules of rosacea occurred in clinical studies, efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated.

IMPORTANT SAFETY INFORMATION

FINACEA is for dermatologic use only, and not for ophthalmic, oral, or intravaginal use. FINACEA is contraindicated in individuals with a history of hypersensitivity to propylene glycol or any other component of the formulation. In clinical trials, sensations of burning/stinging/tingling occurred in 29% of patients, and itching in 11%, regardless of the relationship to therapy. Post-marketing safety—Skin: facial burning and irritation; Eyes: iridocyclitis on accidental exposure to the eye. There have been isolated reports of hypopigmentation after use of azelaic acid. Since azelaic acid has not been well studied in patients with dark complexion, these patients should be monitored for early signs of hypopigmentation.

Desonate® (desonide) Gel, 0.05%

INDICATION AND USAGE

Desonate Gel is indicated for the treatment of mild to moderate atopic dermatitis in patients 3 months of age and older.

IMPORTANT SAFETY INFORMATION

Desonate is contraindicated in those with a history of hypersensitivity to any of the components of the preparation. Topical corticosteroids can produce reversible hypothalamic pituitary adrenal (HPA) axis suppression, Cushing's syndrome and unmask latent diabetes. Systemic absorption may require evaluation for HPA axis suppression. Modify use should HPA axis suppression develop. Potent corticosteroids, use on large areas, prolonged use or occlusive use may increase systemic absorption.

Pediatric patients may be more susceptible to systemic toxicity when treated with topical corticosteroids due to their larger skin surface-to-body mass ratios. Unless directed by a physician, do not use on the underarm or groin area of children. Do not use to treat diaper dermatitis. Use in children less than 3 months of age is not recommended.

Local adverse reactions may include atrophy, striae, irritation, acneiform eruptions, hypopigmentation and allergic contact dermatitis and may be more likely with occlusive use or more potent corticosteroids. The most common adverse reactions (incidence ≥ 1%) are headache, application site burning and rash. **To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare at 1-866-463-3634 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.**

Not for ophthalmic, oral or intravaginal use. As with other corticosteroids, therapy should be discontinued when control is achieved. Safety beyond 4 weeks has not been established.

Bayer HealthCare